Firalis launches its Healthy Volunteer Clinical Study (HVCS)
Firalis SAS, sponsor of HVCS, welcomed its first volunteer on June 18, 2025. The study tests biomarker stability in blood, urine, saliva and buccal cells.
Media
ONCOSCREEN partners meet in Kaunas to advance risk-based colorectal cancer screening
The European project held its second plenary meeting in Kaunas, Lithuania. Firalis leads biomarker identification and the clinical trial work.
Firalis joins VOLABIOS, a European project on the early diagnosis of schizophrenia
VOLABIOS started on January 1, 2025 with 18 partners from 11 European countries. Firalis contributes biomarker validation and its biobank.
CombiDiag doctoral candidates present their research at Firalis
Doctoral candidates of the CombiDiag network presented their thesis work at Firalis in June 2024, with talks by experts and a tour of the site.
COVIRNA presents its results at its final conference in Brussels
Built on the Firalis FiMICS® panel of cardiac RNAs, the European project COVIRNA closed with a final conference in Brussels on April 19, 2023.
PARADISE, a European project on relapse risk in autoimmune disease, launches with Firalis as partner
Coordinated by the ADAPT Centre at Trinity College Dublin, PARADISE develops a personalised tool to predict relapse in vasculitis, with Firalis as partner.
Firalis obtains ISO 14001 environmental certification
Firalis SAS is certified ISO 14001 for the development, production and sale of in vitro diagnostic tests, and for the storage and analysis of samples.
Firalis joins PACIFIC to redefine heart failure with preserved ejection fraction
Initiated by Sanofi and Servier, PACIFIC studies HFpEF with AP-HP and Inserm. Firalis contributes soluble and molecular diagnostic biomarkers.
Firalis and Celemics launch FiMICS®, a panel of cardiac-enriched long non-coding RNAs
Developed with Celemics and the Cardiolinc™ network, the FiMICS® research panel quantifies more than 3,200 cardiac-enriched lncRNAs in peripheral blood.
Firalis launches BIOPRED, a targeted mRNA panel for inflammatory and autoimmune disorders
The BIOPRED research panel profiles over 2,100 inflammatory-pathway mRNAs from whole blood without RNA extraction, building on BT-Cure and RABIOPRED.
Media enquiries